Cross-Talk Between Cardiac Muscle and Coronary Vasculature
... Heterogeneity in flow between control and moderate dilation differs little (99) but is different during maximal vasodilation (23). This heterogeneity depends on perfusion pressure (127) and on the perfusate (285); therefore, it is only partially dependent on the anatomy. Heterogeneity of flow is pre ...
... Heterogeneity in flow between control and moderate dilation differs little (99) but is different during maximal vasodilation (23). This heterogeneity depends on perfusion pressure (127) and on the perfusate (285); therefore, it is only partially dependent on the anatomy. Heterogeneity of flow is pre ...
Contemporary Echocardiography In Non
... Non-ST Elevation Myocardial Infarction – An Overview ................................ 17 ...
... Non-ST Elevation Myocardial Infarction – An Overview ................................ 17 ...
Risk scores: a guide in clinical practice? Application of risk scores in
... College of Cardiology (AHA/ACC) guidelines summarize all available scientific evidence regarding diagnosis, risk stratification, early pharmacological treatment, invasive procedures, and secondary prevention strategies in NST-ACS [2,3]. The guidelines can be used in selecting appropriate treatment f ...
... College of Cardiology (AHA/ACC) guidelines summarize all available scientific evidence regarding diagnosis, risk stratification, early pharmacological treatment, invasive procedures, and secondary prevention strategies in NST-ACS [2,3]. The guidelines can be used in selecting appropriate treatment f ...
this PDF file
... range of therapeutic applications. In the past two decades, considerable progress has been made in the development of biodegradable polymeric materials, mainly in the biomedical and pharmaceutical industries due to their versatility, biocompatibility and biodegradability properties. The present revi ...
... range of therapeutic applications. In the past two decades, considerable progress has been made in the development of biodegradable polymeric materials, mainly in the biomedical and pharmaceutical industries due to their versatility, biocompatibility and biodegradability properties. The present revi ...
ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012
... the ACCF to critically and systematically create, review, and categorize clinical situations where diagnostic tests and procedures are utilized by physicians caring for patients with cardiovascular diseases. The process is based on current understanding of the technical capabilities of the imaging m ...
... the ACCF to critically and systematically create, review, and categorize clinical situations where diagnostic tests and procedures are utilized by physicians caring for patients with cardiovascular diseases. The process is based on current understanding of the technical capabilities of the imaging m ...
Effect of High (200 μg/kg per Minute)
... 3-minute adenosine (140 lg/kg per minute) infusion. Thirty patients agreed to participate in a post 5-minute repeat fractional flow reserve assessment using 200 lg/kg per minute 3-minute adenosine infusion. The study’s co-primary end point of Pd/Pa coefficient of dispersion was lower for the high vers ...
... 3-minute adenosine (140 lg/kg per minute) infusion. Thirty patients agreed to participate in a post 5-minute repeat fractional flow reserve assessment using 200 lg/kg per minute 3-minute adenosine infusion. The study’s co-primary end point of Pd/Pa coefficient of dispersion was lower for the high vers ...
Infarct Size and Myocardial Function
... The size of a myocardial infarction (MI) and the concurrent effect on left ventricular (LV) function are essential for decisions regarding patient care and treatment. Images produced with the late gadolinium enhancement (LGE) technique visualize the scar with high spatia ...
... The size of a myocardial infarction (MI) and the concurrent effect on left ventricular (LV) function are essential for decisions regarding patient care and treatment. Images produced with the late gadolinium enhancement (LGE) technique visualize the scar with high spatia ...
Implications of Recent Clinical Trials for the National Cholesterol
... trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol man ...
... trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol man ...
ACC/AHA Guidelines for the Management of Patients With Acute
... only published information available. Several new references have been incorporated into the text since the original publication of these guidelines in 1996. The new references are numbered 788849 and are listed together at the end of the reference list. The emphasis of the committee's review reflec ...
... only published information available. Several new references have been incorporated into the text since the original publication of these guidelines in 1996. The new references are numbered 788849 and are listed together at the end of the reference list. The emphasis of the committee's review reflec ...
ACC/AHA Guidelines for the Management of Patients With Acute
... only published information available. Several new references have been incorporated into the text since the original publication of these guidelines in 1996. The new references are numbered 788849 and are listed together at the end of the reference list. The emphasis of the committee's review reflec ...
... only published information available. Several new references have been incorporated into the text since the original publication of these guidelines in 1996. The new references are numbered 788849 and are listed together at the end of the reference list. The emphasis of the committee's review reflec ...
ACC/AHA Practice Guidelines
... The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide d ...
... The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide d ...
Segment of Left Pulmonary Artery
... at 14 months of age. The only cardiovascular anomaly was absence of the primary division of the right pulmonary artery. The right pulmonary artery was connected to the right innominate artery by an obliterated ductus. In the collected series of Pool and associates,7 there were 32 patients with "abse ...
... at 14 months of age. The only cardiovascular anomaly was absence of the primary division of the right pulmonary artery. The right pulmonary artery was connected to the right innominate artery by an obliterated ductus. In the collected series of Pool and associates,7 there were 32 patients with "abse ...
Evaluation of transmural distribution of viable muscle by - AJP
... Evaluation of transmural distribution of viable muscle by myocardial strain profile and dobutamine stress echocardiography. Am J Physiol Heart Circ Physiol 292: H921–H927, 2007. First published September 29, 2006; doi:10.1152/ajpheart.00019.2006.—Transmural distribution of viable myocardium in the i ...
... Evaluation of transmural distribution of viable muscle by myocardial strain profile and dobutamine stress echocardiography. Am J Physiol Heart Circ Physiol 292: H921–H927, 2007. First published September 29, 2006; doi:10.1152/ajpheart.00019.2006.—Transmural distribution of viable myocardium in the i ...
Coronary flow reserve as a physiologic measure of stenosis severity
... physiologic variables. Stenosis flow reserve is derived from length, percent stenosis, absolute diameters and shape by quantitative coronary arteriography using standardized physiologic conditions. To study the relative merits of absolute coronary flow reserve measured by flow meter and stenosis flo ...
... physiologic variables. Stenosis flow reserve is derived from length, percent stenosis, absolute diameters and shape by quantitative coronary arteriography using standardized physiologic conditions. To study the relative merits of absolute coronary flow reserve measured by flow meter and stenosis flo ...
Guidelines for the Management of Patients with Acute Myocardial
... of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www.acc.org. These guidelines have been reviewed over the course of the past 2 and 1/2 years since their initial publication in the Journal of the America ...
... of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www.acc.org. These guidelines have been reviewed over the course of the past 2 and 1/2 years since their initial publication in the Journal of the America ...
Instructions For Use
... The ADVANCE study was a single-cohort, open-label trial that enrolled 50 patients with either unilateral or bilateral ethmoid sinus disease at 7 study centers. Follow-up assessments included endoscopic examination and scoring through 2 months, with patient symptom scoring done through 6 months (Sino ...
... The ADVANCE study was a single-cohort, open-label trial that enrolled 50 patients with either unilateral or bilateral ethmoid sinus disease at 7 study centers. Follow-up assessments included endoscopic examination and scoring through 2 months, with patient symptom scoring done through 6 months (Sino ...
ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac
... Class IIb: Usefulness/efficacy is less well established by evidence/opinion. Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful. Levels of evidence for individual class assignments are desig ...
... Class IIb: Usefulness/efficacy is less well established by evidence/opinion. Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful. Levels of evidence for individual class assignments are desig ...
Acute coronary syndrome secondary to methylphenidate overdose
... reported in patients with co-ingestion of methylphenidate and ethanol. In contrast to cocaethylene which is a potent cardiotoxic compound formed by cocaineethanol metabolic transesterification in humans,11 the clinical significance and toxicity of ethylphenidate are unknown. The presence of ethylphe ...
... reported in patients with co-ingestion of methylphenidate and ethanol. In contrast to cocaethylene which is a potent cardiotoxic compound formed by cocaineethanol metabolic transesterification in humans,11 the clinical significance and toxicity of ethylphenidate are unknown. The presence of ethylphe ...
ACC/AHA Practice Guidelines
... executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588 – 636. Copies: This document and the full-text guideline are available on the World Wide We ...
... executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588 – 636. Copies: This document and the full-text guideline are available on the World Wide We ...
product information
... properly validated endpoints to measure morbidity and/or mortality in patients with atherosclerotic coronary artery disease associated with hypercholesterolaemia. Prevention of coronary heart disease: Pravastatin is effective in reducing the risk of coronary heart disease death (fatal myocardial inf ...
... properly validated endpoints to measure morbidity and/or mortality in patients with atherosclerotic coronary artery disease associated with hypercholesterolaemia. Prevention of coronary heart disease: Pravastatin is effective in reducing the risk of coronary heart disease death (fatal myocardial inf ...
plavix* data sheet
... Experience with clopidogrel is limited in patients with severe renal impairment. Therefore clopidogrel should be used with caution in this population. Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses. Clopidogrel should therefore be used with caution in ...
... Experience with clopidogrel is limited in patients with severe renal impairment. Therefore clopidogrel should be used with caution in this population. Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses. Clopidogrel should therefore be used with caution in ...
Low-Dose Aspirin for the Prevention of Atherothrombosis
... uncontrolled progression of such a process through a series of self-sustaining amplification loops may lead to the intraluminal formation of thrombus, vascular occlusion, and transient ischemia or infarction. The ability of platelets to participate in both normal hemostasis and atherothrombosis depe ...
... uncontrolled progression of such a process through a series of self-sustaining amplification loops may lead to the intraluminal formation of thrombus, vascular occlusion, and transient ischemia or infarction. The ability of platelets to participate in both normal hemostasis and atherothrombosis depe ...
Pravachol
... mortality by 25% (p<0.0001). The risk for undergoing myocardial revascularisation procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) was significantly reduced by 20% (p<0.0001) in the pravastatin treated patients. Pravastatin also significantly reduced the ...
... mortality by 25% (p<0.0001). The risk for undergoing myocardial revascularisation procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) was significantly reduced by 20% (p<0.0001) in the pravastatin treated patients. Pravastatin also significantly reduced the ...
ACC/AHA/ACP-ASIM Guidelines for the Management
... the presence of coronary artery anomalies. Patients with chest pain syndromes following cardiac transplantation are also not included in these guidelines. Patients with nonanginal chest pain are generally at lower risk for ischemic heart disease. Often their chest pain syndromes have identifiable no ...
... the presence of coronary artery anomalies. Patients with chest pain syndromes following cardiac transplantation are also not included in these guidelines. Patients with nonanginal chest pain are generally at lower risk for ischemic heart disease. Often their chest pain syndromes have identifiable no ...
Effects of myocardial ischemia on the release of cardiac troponin i in
... marker is more specific than CK-MB, LD, and myoglobin. 11 In cardiac surgery, cardiac troponin I is efficient in the diagnosis of perioperative myocardial infarction. Mair and associates 12 showed that cardiac troponin I increased in all patients after coronary artery bypass grafting, but the concen ...
... marker is more specific than CK-MB, LD, and myoglobin. 11 In cardiac surgery, cardiac troponin I is efficient in the diagnosis of perioperative myocardial infarction. Mair and associates 12 showed that cardiac troponin I increased in all patients after coronary artery bypass grafting, but the concen ...
Drug-eluting stent
A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombi), could otherwise block the stented artery, a process called restenosis. The stent is usually placed within the peripheral or coronary artery by an interventional cardiologist or interventional radiologist during an angioplasty procedure.Drug-eluting stents in current clinical use were approved by the FDA after clinical trials showed they were statistically superior to bare-metal stents for the treatment of native coronary artery narrowings, having lower rates of major adverse cardiac events (usually defined as a composite clinical endpoint of death + myocardial infarction + repeat intervention because of restenosis). The first drug-eluting stents to be approved in Europe and the U.S. were coated with paclitaxel or an mTOR inhibitor, such as sirolimus.